Prescription Digital Therapeutics, or PDTs, are a new therapeutic class.
Similar to traditional biologics or drugs, PDTs:
- Directly treat serious diseases
- Are built under current Good Manufacturing Practices
- Demonstrate safety and efficacy in randomized clinical trials
- Receive labeled claims from the FDA
- Are used by physician prescription
- Are reimbursed as products, via Pharmacy and Medical benefits
- Have barriers to entry that span regulatory exclusivity and intellectual property
Pear Therapeutics is the leader in this new sector and has built a pipeline of potential new therapies across disease areas.
